Abstract
Stefano Molica is Chief of the Department of Hematology–Oncology at the Azienda Ospedaliera “Pugliese-Ciaccio” (Catanzaro, Italy). He is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and European Hematology Association, and is actively involved in the Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) lymphoproliferative working group as a member of the working party. His current research is focused on investigating the impact of novel laboratory parameters useful for assessing the prognosis of chronic lymphocytic leukemia (CLL) and studying the role of angiogenesis in the disease. From a clinical standpoint he is actively involved in the management and treatment of patients with hematological malignancies and, particularly, those suffering from lymphoproliferative disorders. He has published 138 peer-reviewed papers primarily in the field of CLL and CLL-related disorders. He is a member of the editorial board of International Journal of Hematologic Oncology, as well as Leukemia & Lymphoma, BMC Medicine and ISRN Hematology. Molica currently serves or has served as a referee for several hematology–oncology journals, such as Journal of Clinical Oncology, Blood, Haematologica, British Journal of Haematology, Leukemia Research, Leukemia, Leukemia & Lymphoma, European Journal of Haematology and Cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
